Silence Therapeutics Files 8-K
Ticker: SLNCF · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulation-fd
TL;DR
Silence Therapeutics filed a standard 8-K, no major news.
AI Summary
On January 2, 2025, Silence Therapeutics plc filed an 8-K report to disclose information under Regulation FD. The filing does not contain specific details about new events, agreements, or financial figures, but serves as a notification of reporting.
Why It Matters
This filing indicates Silence Therapeutics plc is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- January 2, 2025 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is a current report filed by Silence Therapeutics plc to disclose information under Regulation FD.
What is the date of the earliest event reported?
The date of the earliest event reported is January 2, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 72 Hammersmith Road, London, United Kingdom, W14 8TH.
What is the company's telephone number?
The company's telephone number is +44 20 3457 6900.
Is this filing intended to satisfy any other reporting obligations?
The filing explicitly states it is not intended to simultaneously satisfy the filing obligations under Rule 425 or Rule 14a-12 of the Securities Act or Exchange Act.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-01-02 08:00:25
Filing Documents
- d921843d8k.htm (8-K) — 19KB
- 0001193125-25-000144.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILENCE THERAPEUTICS PLC Dated: January 2, 2025 By: /s/ Craig Tooman Name: Craig Tooman Title: Chief Executive Officer